The positive results of the IMbrave150 trial, in which the combination of the anti-programmed death ligand 1 (PD-L1) atezolizumab and the anti-vascular endothelial growth factor A (VEGF-A) bevacizumab definitely demonstrated its superiority compared to sorafenib in patients with advanced stage HCC [7], are of the utmost importance. This evidence concerns the gene VEGFA and hepatocellular carcinoma.